Last reviewed · How we verify
NCT06218290
A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
Phase 2 trial testing Oxylanthanum Carbonate in Chronic Kidney Disease Requiring Chronic Dialysis in 106 participants. Completed in 29 May 2024.
29 May 2024
Quick facts
| Lead sponsor | Unicycive Therapeutics, Inc |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 106 |
| Start date | 15 December 2023 |
| Primary completion | 29 May 2024 |
| Estimated completion | 29 May 2024 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Oxylanthanum Carbonate — full drug profile →
Conditions studied
- Chronic Kidney Disease Requiring Chronic Dialysis — all drugs for Chronic Kidney Disease Requiring Chronic Dialysis →
Sponsor
Unicycive Therapeutics, Inc
Who can join
18 and older, any sex, with Chronic Kidney Disease Requiring Chronic Dialysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical study is to test the tolerability of oxylanthanum carbonate (OLC) in patients with chronic kidney disease on hemodialysis and have hyperphosphatemia (too much phosphorus in their blood). The main question it aims to answer is whether patients taking OLC for hyperphosphatemia are able to tolerate the drug. Participants will continue with their scheduled dialysis treatments and replace their current phosphate binder drug with OLC.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between Oxylanthanum Carbonate and Lanthanum Carbonate.
Mathur V, Walker M, Hasal S, Reddy G, et al · · 2025 · cited 1× · PMID 39617673 · DOI 10.1016/j.clinthera.2024.11.009
Verify or expand the search:
- PubMed search for NCT06218290
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Disease Requiring Chronic Dialysis
Currently open trials in the same condition.
- NCT07332949 — Impact of Dialysis on Sexuality. · recruiting
- NCT06873880 — Integrating BIA and eGFR for Nutritional Status in Hemodialysis Patients · recruiting
- NCT06225544 — Lumasiran in Hyperoxalaemic Patients on Haemodialysis · Phase 2 · recruiting
- NCT06591702 — Investigation of the Validity, Reliability, and Responsiveness of BETY-BQ in Chronic Kidney Disease, on Dialysis, and Ki · recruiting
- NCT06040281 — Smart and Fit for Kidney Transplantation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06218290 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Unicycive Therapeutics, Inc
- Last refreshed: 24 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06218290.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing